Celcuity Inc
(NASDAQ:CELC)
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
top performing CELC trades
![Tom Malinowski headshot](https://clerk.house.gov/content/assets/img/members/M001203.jpg)
Tom Malinowski
House (D-NJ)
-29.00%
Recent Trades
Largest Trades
Top Performing
Largest Traders
Most Active Traders
Recent Trades
View the most recent Celcuity trades made by congress members.
![]() Tom MalinowskiHouse (D-NJ) | $1K - $15K | Sale | Jun 23, 2021 | May 26, 2021 | House |